Marcadia Moves Diabetes Candidate Forward

February 2010
Bioworld Week;2/22/2010, Vol. 18 Issue 8, p3
The article reports that Marcadia Biotech Inc. has remained its low profile since its founding in 2006, however, it has stayed busy raising funds and entering a peptides collaboration with Merck & Co. Inc.


Related Articles

  • Marcadia Adds to Diabetes Deal Flow.  // BioWorld Today;6/29/2010, Vol. 21 Issue 124, p5 

    The article reports on a glucagon analogue partnership unveiled by Marcadia Biotech Inc. with Eli Lilly and Co.

  • Merck, Pfizer announce collaboration on drug. Zanki, To // njbiz;5/6/2013, p2 

    This article reports on a partnership between pharmaceutical firms Merck & Co. Inc. and Pfizer Inc. to develop and market the latter's experimental Type 2 diabetes drug, Ertugliflozin.

  • Merck Partnering Strong Under New Management.  // BioWorld Today;3/2/2012, Vol. 23 Issue 42, p6 

    The article reports on the strong partnering activity of Merck and Co. Inc. under the leadership of new chief executive officer (CEO) Ken Franzier as evidenced by the 50 licensing and partnership deals completed by the company in 2011.

  • Clarification.  // BioWorld Today;2/13/2013, Vol. 24 Issue 30, p2 

    A correction to the article regarding the goal of Merck and Co. Inc. and Lycera Corp.'s collaboration that was published in the February 12, 2013 issue is presented.

  • Merck, Greenpharma collaborate on cosmetic active ingredient.  // BioSpectrum;Aug2013, Vol. 11 Issue 8, p14 

    The article reports on the collaboration between pharmaceutical companies Merck & Co. Inc. and Greenpharma S.A.S. to market the active cosmetic ingredient of the extract of poppy seeds in India.

  • Riboswitching: BioRelix Inks Antibacterial Merck Deal.  // Bioworld Week;10/11/2010, Vol. 18 Issue 41, p2 

    The article focuses on the partnership deal between BioRelix Inc. and Merck & Co. Inc.

  • Merck Backs Out of Two Galapagos Partnerships.  // Bioworld Week;2/14/2011, Vol. 19 Issue 7, p3 

    The article reports on the move of Merck & Co. Inc. to withdraw its partnership with Galapagos NV.

  • Delivering knowledge where it's needed .  // Australian Nursing Journal;Dec2001/Jan2002, Vol. 9 Issue 6, p19 

    Deals with the partnership formed by the International Council for Nurses (ICN) with Merck and Co. Inc. and medical publisher Harcourt of the United States. Objectives of the partnership program; Views of ICN on the education of nurses.

  • Ambrx Taking ADCs Beyond Cancer in $303M Merck Deal. Boggs, Jennifer // BioWorld Today;6/19/2012, Vol. 23 Issue 118, p1 

    The article reports on a potential 303 million U.S. dollar collaboration of San Diego, California-based biopharmaceutical firm Ambrx Inc. with Merck & Co. Inc., making use of its EuCODE platform to develop antibody-drug conjugates (ADCs) against oncology and other indications, as of June 2012.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics